AstraZeneca to test blood cancer drug Calquence in COVID-19 after NIH sees 'some clinical benefit'

14th April 2020 Uncategorised 0

Add another drugmaker that’s repurposing existing med for COVID-19. AstraZeneca is now kicking off a clinical trial testing BTK inhibitor Calquence to help control dangerous immune complications in serious patients after researchers at the NIH’s National Cancer Institute observed “some clinical benefit.”

More: AstraZeneca to test blood cancer drug Calquence in COVID-19 after NIH sees 'some clinical benefit'
Source: fierce